ATE402995T1 - Akt-3 nukleinsäure, polypeptide und deren verwendung - Google Patents
Akt-3 nukleinsäure, polypeptide und deren verwendungInfo
- Publication number
- ATE402995T1 ATE402995T1 AT00917899T AT00917899T ATE402995T1 AT E402995 T1 ATE402995 T1 AT E402995T1 AT 00917899 T AT00917899 T AT 00917899T AT 00917899 T AT00917899 T AT 00917899T AT E402995 T1 ATE402995 T1 AT E402995T1
- Authority
- AT
- Austria
- Prior art keywords
- polypeptides
- act
- nucleic acid
- akt3
- relates
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- -1 ACT-3 NUCLEIC ACID Chemical class 0.000 title 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 title 1
- 101150051155 Akt3 gene Proteins 0.000 abstract 2
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 102000057471 human AKT3 Human genes 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12510899P | 1999-03-19 | 1999-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402995T1 true ATE402995T1 (de) | 2008-08-15 |
Family
ID=22418217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00917899T ATE402995T1 (de) | 1999-03-19 | 2000-03-14 | Akt-3 nukleinsäure, polypeptide und deren verwendung |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1144600B1 (enExample) |
| JP (1) | JP4237945B2 (enExample) |
| KR (1) | KR100700908B1 (enExample) |
| AT (1) | ATE402995T1 (enExample) |
| AU (1) | AU782448B2 (enExample) |
| BR (1) | BR0009170A (enExample) |
| CA (1) | CA2343074C (enExample) |
| CY (1) | CY1108459T1 (enExample) |
| DE (1) | DE60039677D1 (enExample) |
| DK (1) | DK1144600T3 (enExample) |
| ES (1) | ES2310515T3 (enExample) |
| HK (1) | HK1041288B (enExample) |
| IL (4) | IL141984A0 (enExample) |
| NO (1) | NO20014537L (enExample) |
| PT (1) | PT1144600E (enExample) |
| SI (1) | SI1144600T1 (enExample) |
| WO (1) | WO2000056866A2 (enExample) |
| ZA (1) | ZA200108414B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| WO2000062605A1 (en) | 1999-04-16 | 2000-10-26 | Yale University | eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
| WO2000077190A2 (en) * | 1999-06-11 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| JPWO2003063905A1 (ja) * | 2002-01-31 | 2005-05-26 | 株式会社東京大学Ｔｌｏ | 免疫疾患の予防又は治療剤 |
| US20060051407A1 (en) * | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
| US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| EP1661581A1 (en) * | 2003-07-28 | 2006-05-31 | Osaka Industrial Promotion Organization | Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
| EP2599793A1 (en) * | 2008-05-29 | 2013-06-05 | Nuclea Biotechnologies, Inc. | Anti-phospho-akt antibodies |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| CN102985418B (zh) | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| ES2731602T3 (es) | 2014-09-24 | 2019-11-18 | Gilead Sciences Inc | Métodos para tratar la enfermedad hepática |
| CA3100432C (en) | 2014-12-23 | 2023-08-08 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| WO2020180886A1 (en) * | 2019-03-04 | 2020-09-10 | The Trustees Of The University Of Pennsylvania | Neuroprotective gene therapy targeting the akt pathway |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08109197A (ja) * | 1994-10-07 | 1996-04-30 | Sumitomo Electric Ind Ltd | 白血病腫瘍拒絶抗原ペプチド |
| DE69633186T2 (de) * | 1995-11-16 | 2005-08-18 | Novartis Ag | Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren |
| US5958773A (en) * | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| GB9828375D0 (en) * | 1998-12-22 | 1999-02-17 | Janssen Pharmaceutica Nv | Human akt-3 |
| US6043090A (en) * | 1999-03-23 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Akt-2 expression |
| CA2383592A1 (en) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| WO2000077190A2 (en) * | 1999-06-11 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
-
2000
- 2000-03-14 EP EP00917899A patent/EP1144600B1/en not_active Expired - Lifetime
- 2000-03-14 AT AT00917899T patent/ATE402995T1/de active
- 2000-03-14 JP JP2000606725A patent/JP4237945B2/ja not_active Expired - Fee Related
- 2000-03-14 WO PCT/US2000/006574 patent/WO2000056866A2/en not_active Ceased
- 2000-03-14 BR BR0009170-7A patent/BR0009170A/pt not_active Application Discontinuation
- 2000-03-14 DK DK00917899T patent/DK1144600T3/da active
- 2000-03-14 PT PT00917899T patent/PT1144600E/pt unknown
- 2000-03-14 CA CA2343074A patent/CA2343074C/en not_active Expired - Fee Related
- 2000-03-14 IL IL14198400A patent/IL141984A0/xx unknown
- 2000-03-14 ES ES00917899T patent/ES2310515T3/es not_active Expired - Lifetime
- 2000-03-14 AU AU38802/00A patent/AU782448B2/en not_active Ceased
- 2000-03-14 IL IL14551400A patent/IL145514A0/xx unknown
- 2000-03-14 SI SI200031007T patent/SI1144600T1/sl unknown
- 2000-03-14 DE DE60039677T patent/DE60039677D1/de not_active Expired - Lifetime
- 2000-03-14 HK HK02102803.1A patent/HK1041288B/en not_active IP Right Cessation
- 2000-03-14 KR KR1020017011960A patent/KR100700908B1/ko not_active Expired - Fee Related
-
2001
- 2001-09-18 NO NO20014537A patent/NO20014537L/no unknown
- 2001-09-20 IL IL145514A patent/IL145514A/en not_active IP Right Cessation
- 2001-10-12 ZA ZA200108414A patent/ZA200108414B/xx unknown
-
2008
- 2008-03-18 IL IL190270A patent/IL190270A/en not_active IP Right Cessation
- 2008-10-27 CY CY20081101217T patent/CY1108459T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1144600B1 (en) | 2008-07-30 |
| NO20014537D0 (no) | 2001-09-18 |
| DK1144600T3 (da) | 2008-11-24 |
| AU3880200A (en) | 2000-10-09 |
| DE60039677D1 (de) | 2008-09-11 |
| PT1144600E (pt) | 2008-10-10 |
| WO2000056866A2 (en) | 2000-09-28 |
| CY1108459T1 (el) | 2013-09-04 |
| WO2000056866A9 (en) | 2002-08-29 |
| EP1144600A2 (en) | 2001-10-17 |
| SI1144600T1 (sl) | 2008-12-31 |
| IL141984A0 (en) | 2002-03-10 |
| BR0009170A (pt) | 2002-04-30 |
| AU782448B2 (en) | 2005-07-28 |
| IL145514A0 (en) | 2002-06-30 |
| HK1041288B (en) | 2008-11-07 |
| NO20014537L (no) | 2001-10-31 |
| JP2002539781A (ja) | 2002-11-26 |
| CA2343074C (en) | 2010-09-21 |
| WO2000056866A3 (en) | 2001-02-15 |
| KR20020011972A (ko) | 2002-02-09 |
| ZA200108414B (en) | 2003-03-26 |
| KR100700908B1 (ko) | 2007-03-29 |
| CA2343074A1 (en) | 2000-09-28 |
| JP4237945B2 (ja) | 2009-03-11 |
| HK1041288A1 (en) | 2002-07-05 |
| IL145514A (en) | 2010-05-17 |
| ES2310515T3 (es) | 2009-01-16 |
| IL190270A (en) | 2012-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108459T1 (el) | Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων | |
| DK0559884T3 (da) | Rekombinante virusvektorer til ekspression i muskelceller | |
| DE3684892D1 (de) | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens. | |
| DE602005021509D1 (de) | Modifizierte vitamin-k-abhängige polypeptide | |
| DE69429260D1 (de) | Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie | |
| DK1317537T3 (da) | Sammensætninger og fremgangsmåder med G-CSF analoger | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| NZ505063A (en) | Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| ATE419357T1 (de) | Dna 19355 polypeptide, ein homolog des tumornekrosefaktors | |
| EP0232523A3 (en) | Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins | |
| TR200102985T2 (tr) | Gen tedavisi teknikleri. | |
| EE200000102A (et) | Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene | |
| NZ516237A (en) | Meth1 and meth2 polynucleotides and polypeptides | |
| WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
| DK0676413T3 (da) | Inteferon-alfa/beta-bindingsprotein, dets fremstilling og anvendelse | |
| BRPI0415296A (pt) | cdna modificado para os nìveis de expressão elevados do fator viii e seus derivados | |
| Basílico et al. | UV-specific DNA repair recombinant fusion enzyme: A new stable pharmacologically active principle suitable for photoprotection | |
| ATE466588T1 (de) | Bakteriophagen- und prophagen-proteine in der krebsgentherapie | |
| EP1427825B8 (en) | Cdna encoding the human alpha2 delta4 calcium channel subunit | |
| WO2002034882A3 (en) | Genes regulating programmed cell death | |
| CY1113344T1 (el) | Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1144600 Country of ref document: EP |